In fact, we found a clear trend, albeit not statistically significant, toward an increase in the 2-year retention rate in patients maintaining high-dose MTX compared with subjects undergoing MTX dose reduction/discontinuation.
← all excerpts
The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry.
1
—
—